SeenewsSeenews
Search
Seenews
AlertsSeenewsSeenews
Searchclose
TOPICS
arrow
COUNTRIES
arrow
INDUSTRY
arrow
Economy
arrow
Browse Economy
Mix and match your focus countries with our advanced search
Investments
arrow
Browse Investments
Mix and match your focus countries with our advanced search
Politics
arrow
Browse Politics
Latest in Politics
Deals
arrow
Browse Deals
Mix and match your focus countries with our advanced search
Tech
arrow
Browse Tech
Mix and match your focus countries with our advanced search
Green
arrow
Browse Green
Mix and match your focus countries with our advanced search
0/5
You have 5 free articles left this month
You have 0/5 free articles
Get your free Basic subscription now and gain instant access to more
SIGN UP
arrow
LOGIN
arrow

Two shareholders of Bosnian drug maker Bosnalijek seek supervisory board overhaul

Jan 26, 2022, 1:10:05 PMArticle by Dragana Petrushevska
share
January 26 (SeeNews) - Bosnian pharmaceuticals producer Bosnalijek [SAJ:BSNLR] said it has received a proposal from two of its shareholders to dismiss the supervisory board and audit committee.

Two shareholders of Bosnian drug maker Bosnalijek seek supervisory board overhaul
Photo: Bosnalijek

Local diversified group AS Holding and drug maker Hercegovinalijek have proposed to replace all of the members of the supervisory board and the audit committee at the shareholders meeting scheduled for February 5, Bosnalijek said in a bourse filing on Tuesday.

AS Holding held a 15.56% stake in Bosnalijek as of January 21, data of the Sarajevo Stock Exchange (SASE) showed. Hercegovinalijek's shareholding interest is not displayed on the bourse's website.

Local media reported in December that police have arrested Bosnalijek's general manager Nedim Uzunovic along with other people suspected of illegal trading in the company's shares. Adnan Hadzic has been acting as interim general manager since then.

Bosnalijek's shares have not traded on the SASE in the past year.

Your complete guide to the emerging economies of Southeast Europe. From latest news to bespoke research – the big picture at the tip of your fingers.